Combination of Serabelisib and Insulin Suppressing Diet in Subjects With Advanced Solid Tumors With PIK3CA Mutations
Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the feasibility of optimizing the safety and tolerability of
serabelisib when combined with an ISD with a goal of reducing side effects and enhancing
anticancer activity.